CRL
Charles River Laboratories
NYSE: CRL · HEALTHCARE · DIAGNOSTICS & RESEARCH
$373.98
+4.22% today
Updated 2026-10-28
Market cap
$17.28B
P/E ratio
—
P/S ratio
4.32x
EPS (TTM)
$-4.80
Dividend yield
—
52W range
$146 – $378
Volume
1.0M
Charles River Laboratories (CRL) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$373.98
12-Month target
—
2030 Target
—
Intrinsic (DCF)
$163.67
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.5B | $4.0B | $4.1B | $4.0B | $4.0B | $4.3B | $4.6B | $4.9B | $5.2B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 6.55% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -5.96%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.